Alonso was also a chemistry professor at the Universidad de los Andes in Colombia. James has over 25 years of industry experience in creating and building biotechnology companies including experience as a co-founder of the lysosomal storage diseases company Vtesse acquired by Sucampo/Malinkrodt, co-founder of the clinical stage neuroendocrine company Tiburio, Board Director of the ocular gene therapy company Nightstar acquired by Biogen, and as founding Chief Scientific Officer of the rheumatology therapy company Synovex/Adheron acquired by Roche. Nadim completed his BS in Biology at Stony Brook University, received his PhD with Distinction in Microbiology at Columbia University, and was an NRSA Postdoctoral Fellow studying the cell biology of HCV in the laboratory of Nobel Prize winner Charles M. Rice at the Rockefeller University. Peter Kolchinsky 285 Followers Scientist turned biotech investor, always learning, guided by fatherhood, share The Economist's world view, inspired to write by Hamilton's Federalist Papers. Christinas primary responsibility is to edit and guide development of competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. James was an entrepreneur in residence at HealthCare Ventures, an advisor to Kurma Ventures, and is on the Scientific Advisory Board and Board of Directors of the Friedreichs Ataxia Research Alliance (FARA), a patient advocacy group. Megan Lipcsey is an Associate with the TechAtlas division of RA Capital Management. Ana holds an MPH in Epidemiology and Biostatistics from Boston University School of Public Health and a BA in Neuroscience from Boston University. Michael Sherman is a Venture Partner at RA Ventures. Chris Morrison is an Editor at RA Capital Management. Prior to his time at Merck, Michael held discovery leadership roles at Immunext and Tolerx. Milind Deshpande is a Venture Partner at RA Capital, and President & CEO of Nayan Therapeutics, a RA Capital portfolio company. Laura has a BS in Human Services; Clinical Concentration and a Minor in Disabilities Studies from the University of Delaware. Jaimie previously held roles as data analyst at Massachusetts Department of Public Health and Anne Arundel Medical Center Department of Medicine. Any views expressed were prepared based upon information available and believed to be reliable at the time such views were written. Prior to BHP, Brigid was at In-Q-Tel (IQT), the strategic investment arm of the CIA and the US Intelligence Community; she co-founded IQT's Australian subsidiary, served as its Managing Director, and built an international program to support a global innovation initiative through investing in the Asian-Pacific region. Peyman Hosseinchi is an Associate within the TechAtlas division of RA Capital Management. Prithviraj Singha Roy is a Senior Associate on the Investment Team at RA Capital Management. Gerald is Vice President of Scientific Operations at RA Ventures (RAVen). Mario received postdoctoral training at the NIH and Mount Sinai School of Medicine in innate immunity and bioinformatics, earned a PhD in microbiology at University of Chile and a MS in Nuclear Physics. Peter founded and serves as a Director ofNo Patient Left Behind, a non-profit advocate for healthcare reforms that would make today's medicines affordable to patients and promote the innovation that gives all of us hope for tomorrow. Prior to RA, Kevin was a postdoctoral associate at the Broad Institute of MIT and Harvard and an EMBO fellow. Prior to joining biotech/pharma, she was a specialist in the corporate finance team at McKinsey & Co, focused on corporate transactions. in Neuroscience from University of Pennsylvania and a PhD in Neuroscience from University of Oxford. Michael received his undergraduate degree at Georgetown University and his medical degree at the Medical University of South Carolina. Zach previously worked as a Science Officer at the California Institute for Regenerative Medicine. Lucas Guevara is a Compliance Counsel at RA Capital Management. Dan studied Network Communications & Information Services at Lincoln Technical. Kaleens primary responsibility is to oversee the initiation, planning, and execution of various projects within the TechAtlas Division. In that role, Joel led teams responsible for advancing more than 40 compounds into clinical development, including Sprycel (dasatinib), which he co-invented. Kat has a BS in Business Administration, majoring in Accounting from the University of Minnesota, Carlson School of Management. He worked previously at Global Prior Art, an intellectual property analysis firm, as a Partner and the Director of the Life Sciences Division. Brackett has a BS in Biology with a minor in Spanish from Davidson College. Prior to RA, Anthony completed the Biopharmaceutical Leadership Development Program at Reata Pharmaceuticals. Garrett has worked cross-functionally across the landscape of in vivo and ex vivo genetic medicine modalities, often at the interface of payload design, platform research and manufacturing, IND-enabling activities, bioanalytical and computational biology, and strategy. Generali's No.3 investor Caltagirone withholds backing for 2022 accounts -sources, Musk says Tesla likely to launch full self-drive technology 'this year', Exclusive: JPMorgan employees gripe about Dimon's return-to-office edict, SpaceX rocket explosion illustrates Elon Musk's 'successful failure' formula, Cucinelli posts 33% rise in Q1 sales, confirms 2023 revenue growth forecast, Exclusive-Peter Thiel, Republican megadonor, won't fund candidates in 2024 - sources, Virginia Governor Youngkin 'humbled' by talk of possible presidential run, European Midday Briefing: Mood Brighter After -2-, Tim Cook unveils new Apple store in India, Morgan Stanley's dealmaking CEO Gorman signals more transactions to come, RA Capital Management LP (Private Equity). Special Projects Operations Manager/Chief of Staff. He holds additional board appointments with several well-respected nonprofit organizations, including the Institute for Clinical and Economic Review (ICER), the Personalized Medicine Coalition, the Harvard Business School Healthcare Initiative, NEHI (Network for Excellence in Health Innovation), and the Massachusetts Rare Disease Advisory Council. Adison previously held posts as an Administrative Assistant and Office Manager at Dyer Brown Architects and as an Executive Assistant to the Principal and Office Manager at bKL Architecture. Currently, he serves as Chief Technology Officer at Danaher, with a focus on new genomic medicines. RA Capital | Team Tyler Kowalski is an InteractiveDesigner at RA Capital Management. Habib Dable is a Venture Partner at RA Ventures (RAVen), focusing on advising and supporting newcos, portfolio companies and executives within RAVen. James holds a BS in Journalism from Boston University and a JD from Boston College Law School. Tyler holds a BA in Finance from the University of Massachusetts, Amherst and a certificate in Interactive Design from Rhode Island School of Design. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. Chriss primary responsibility at RA Capital is to cover the biotech and pharma industry. Her primary responsibilities are to assist with all finance operations related to the Firm. Cristina Ghenoiu is a Principal on the Venture Team at RA Capital Management. Bethany is a Senior Finance Associate at RA Capital Management. David holds a BS in Economics with a minor in Business Administration from University of Colorado Boulder. He holds a BS in Computer Science from Northeastern University. Most recently, Ally spent over five years at Akebia Therapeutics (previously Keryx), where she held Commercial Team Administrator/Internal Meetings Specialist, Sales Team Administrator/Training Specialist and Senior Administrative Assistant roles. Adam received his JD from the University of Virginia School of Law, and his BA from Whittier College. Emilie has previously held similar roles at FLAG Capital Management and Bain Capital. Henry Stusnick is an Associate at RA Capital Management. Dr. Ryan was also a fellow in Geriatric Psychiatry and Neuropsychiatry at Dartmouth-Hitchcock Medical Center. Prior to Avilar, Mr. Grau was CEO at Sojournix, President at Heptares Therapeutics (acquired 2015), CEO at Cortria (acquired 2010), and COO at CombinatoRx (IPO 2005). By Matt Grobar. Maryann Vigliotta is the Vice President of Operations and HR at RA Ventures (RAVen). Prior to Q32 Bio, Maryann worked as the Operations Manager for Surface Oncology and several other biotech start-up companies from discovery research through end of Phase 2 Clinical trials. Kriti Subramanyam is an Associate within the TechAtlas division of RA Capital Management. RA Capital makes no guarantees as to their accuracy or completeness. Katherines primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. EMEA +44 20 7330 7500. Her primary responsibilities are to support our Venture Team by coordinating management agendas, calendars, and external events. Prior to management consulting, Mr. Grau was Director of Marketing & Business Development at a clinical information technology startup. Lorena Chen is a Fund Controller at RA Capital Management. from Yale and practiced as a cardiac anesthesiologist. Prior to joining RA Capital, Mario was Associate Vice President for Advanced Research at Sanofi Pasteur and Head of the team executing a strategy for integrating influenza vaccine development with machine learning and antigen design. Candice has a BS in Mass Communications from Emerson College. He was also responsible for initiating the transition of the autoimmunity strategy from one based on systemic immunosuppression to a targeted immunomodulation approach. Habib brings to RAVen nearly three decades of experience as a strategic leader in Big Pharma and emerging Biotech. Fuad has a BA in Biology with a Minor in Psychology and earned a PhD in Biological Chemistry, both from Washington University in St. Louis. He holds a BS in Computer Science from The University of California, San Diego, and worked previously as a Software Engineer at IBM and Fidelity Investments. Soumya has more than two decades of experience in structure-based drug design and molecular modeling both in the areas of small molecules and biologics across multiple target classes and indications. Habib has earned his Director Professionalism Certificate from the National Association of Corporate Directors. Cosmas brings to RAVen over a decade of leadership experiences at the interface of basic science, drug development and clinical care. Joels first role in Biotech was as Chief Scientific Officer at Achillion Pharmaceuticals, where he led discovery efforts on Factor D inhibitors for the treatment of Paroxysmal Nocturnal Hemoglobinuria and C3 Glomerulopathy. Matt Beverly is a Senior Software Engineer at RA Capital Management. She also has a Master's in Accounting from Boston College and is a CPA. In his most recent role as Entrepreneur In Residence at RA Ventures (RAVen), Michael worked closely with the Venture Team to evaluate drug discovery platforms and initiate novel therapeutic programs. Prior to joining Aberdeen, Eric worked as a Compliance Examiner at the US Securities and Exchange Commission. Prior to RAVen, Natalie served as an EA for three years at Massachusetts Technology Collaborative (MassTech), a Boston agency supporting business formation and growth in the state's technology sector. Jessica manages RA's Innovator Resources and co-founded RApport, our biotech communications platform. David is Director of Treasury at RA Capital Management. Prior to Epirium, she was an investor on the Biotech Team at Longitude Capital. Michael earned a DVM at the University of Pretoria and a PhD in Immunology at the University of Pennsylvania. Joe brings to RA fifteen years of IT experience, beginning at the Apple Store and then transitioning to Boston Public Schools as an Apple Support Specialist. Michaels primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. He holds BA and MA degrees in immunology from the University of Cambridge, an MD from University College London, and an MAS in clinical research from UCSF. April 28, 2023 9:39am. She holds a BS in Corporate Finance & Accounting and an MBA from Salem State University. Jessica holds a BA in Linguistics from Brigham Young University and a PhD in auditory neuroscience from the Division of Medical Sciences at Harvard University. She also held research roles at MIT, Children's Hospital, Harvard, and Brigham and Women's Hospital. Prior to Baupost, he spent over five years as a Controller at Centerbridge Partners, LP, where he was responsible for accounting and valuation for the credit fund business, as well as the management company (US and Europe) and associated functions. In preparing the information contained in this website, RA Capital has not taken into account the investment needs, objectives, and financial circumstances of any particular investor, and investments and companies referenced may not be suitable for all investors. He worked previously as an Associate Managing Editor at EBSCO Health, and as a Medical Writer at IC Axon and Publicis Life Brands International. He completed the Executive Program at Stanford University, Graduate School of Business, as well as the Executive to Leader Institute at Korn/Ferry International. Peter Kolchinsky Phone Number, Address, Age, Contact Info, Public Prior to RA, Megan worked as a Gastroenterology Fellow at University of Pittsburgh Medical Center and a Resident Physician, Internal Medicine, at Beth Israel Deaconess Medical Center. Cristina holds a Bachelor of Arts in Biochemistry from Mount Holyoke College and a PhD in Cell Biology and Epigenetics from Cornell University and The Rockefeller University. Dan Guglielmo is IT Operations Associate at RA Capital Management. Angela Pontius is Vice President of Clinical Operations at RA Ventures (RAVen). Mark brings to RAVen more than twenty-five years of leadership experience in the life sciences industryspanning operations, corporate development, legal affairs, and intellectual property. Astha holds a BA in Biochemistry and Molecular Biology (with a minor in Physics) from Clark University. Peter Kolchinsky is a founder and Managing Partner at RA Capital Management and author of The Great American Drug Deal. January 3, 2023 Feb 10th, Ed. Cosmas received his BS in Physics from Massachusetts Institute of Technology and his MD from Rutgers-New Jersey Medical School. The market worked. Joeys primary responsibility is to manage workflows for investor transaction processing and investor reporting in collaboration with the fund's administrator. in Immunology from National Taiwan University College of Medicine, and a PhD in Biomedical Science from The Ohio State University. He was also a Board Member of the Fannie & John Hertz Foundation and served as a judge for the Lemelson-MIT StudentPrize for Inventorship. Sophie received her doctorate in CAR T cell therapy from Kings College London, her pre-clinical medical degree from St Johns College, University of Oxford, and her clinical medical degree from Imperial College London, where she won the Norman C Lake prize for Surgery. Daniel holds both a BS and MS degree in Microbiology and Immunology from McGill University. Previously, Danielle was an Associate at RA Capital, and worked in IP and tech licensing at Seven Bridges Genomics and the MIT Technology Licensing Office, respectively. Receptionist and Facilities Administrator. Gunes conducts due diligence on biotechnology companies at RA Capital. Zach Scheiner is a Principal on the Investment Team at RA Capital Management. At BPS, Joe provided technical support for teachers and staff and was Jamf certified to manage Apple products. Prior to external consulting and engineering, he gained experience in Helpdesk Specialist and Systems Administrator roles at Withum and Edelstein and Company, LLP. The strange and special case of epinephrine | by Peter Kolchinsky | The Prior to RAVen, Emily worked as Director, Talent Acquisition, at Generation Bio, leading hiring across all functions and building out systems to support that growth. Mr. Grau earned his BA with High Honors from Davidson College, where he was awarded a Dana Honor Scholarship and elected to Phi Beta Kappa, and his MPhil, MA, and MAR degrees from Yale University, where he was awarded the Day Graduate Prize and was the recipient of a Mellon Fellowship in the Humanities. Jesse Chen is an EIR at RA Capital. Future In Sight with Peter Kolchinsky - FoodAllergy.org Her primary responsibility is leading and executing full cycle recruiting across all newcos and portfolio companies. Toms primary responsibility is to support all aspects of trade and treasury operations. Rye Lane to Peter Pan & Wendy: the seven best films to watch on TV this Daniels primary responsibilities include creating competitive landscapes of climate change solutions and analyzing investment opportunities across climate technology and applied biotech. Prior to RA, Chris was at Elsevier Business Intelligence, where he served as Writer/Editor and eventually became the Editor in Chief for Biopharmaceuticals and Consumer Products. Peter Kolchinsky, Ph.D. - Forma Therapeutics He is an Enrolled Agent, admitted to practice before the IRS. Her doctoral research investigated the folding and aggregation of gamma-crystallins associated with cataract formation. He has held multiple senior level clinical development positions including Chief Medical Officer at Asceneuron SA and Neurodegeneration Therapeutic Area Head at Novartis. Laura previously worked at WinterWyman where she served as a Senior Associate. Kyle was also the CEO and co-founder of Liquid Light, developer of a proprietary process to make major chemicals from CO2, which was sold to Avantium in 2016. Soumya has contributed to over 75 drug discovery programs ranging from small startups to large pharma, leading to nine development candidates currently in various stages of clinical trials. Samuel Chowdhury is a Software Engineerat RA Capital Management. Kevin's primary responsibilities is to research early-stage projects in collaboration with RAVen team members, Venture Partners, and Entrepreneurs-in-Residence. Cameron has a BA in Neurobiology from Harvard University. No Patient Left Behind | Steering committee | Peter Kolchinsky He also provided additional system administration and training for the desktop engineering team. He earned an MS in chemical engineering and his MBA and PhD in engineering systems from MIT. Jacquelines primary responsibility is to partner with the Investment Team to develop quantitative analyses that inform investment decisions and improve core processes throughout the firm. Mark began his professional career as a life sciences attorney with the law firm of Hale and Dorr (now WilmerHale). In his doctoral research, he investigated clinically translatable treatments for musculoskeletal tissue repair using injectable hydrogels. Prior to joining the team at Enara Sophie was a medical oncologist at Guys and St Thomas NHS Foundation Trust in London, UK (GSTT). Most recently, Joe led the administration and support of all Apple products at Curriculum Associates as an IT Systems Engineer. Mark Boshar is a Venture Partner at RA Ventures (RAVen), focusing on new company creation. This ground-breaking new book, The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines (January 20, 2020), by Peter Kolchinsky, PhD, examines the healthcare landscape through the lens of the biotech social contract with America - the implicit agreement between the biopharmaceutical industry and American society - including the government's role in inventing . He previously held roles as VP Product Manager - Data Services at Charles River Development (a State Street Company) and Senior Business Analyst in Capital Markets at Bain Capital Credit and State Street Global Exchange, DataGX. Sadik holds a bachelor of science degree in Cell and Molecular Biology from Tulane University, and earned his PhD in Microbiology and Immunology from Louisiana State University. Ernestos primary responsibility at RA Capital is to coordinate various technology related initiatives across the company and oversee their initiation, planning, and execution. Christy is a Senior Associate with the TechAtlas division of RA Capital Management. Cristina holds a BA in Molecular Biology with a minor in Business from Washington University in St. Louis, and a PhD in Microbiology and Molecular Genetics from Harvard University. Ernesto Gonzalez is a Business Systems Manager at RA Capital. Ryan has a BS in Business Administration with a concentration in Accounting and Sports Management from Isenberg School of Management at University of Massachusetts, Amherst. Dans primary responsibility at RA Capital is to identify compelling opportunities to help facilitate new company creation or investments in emerging seed-stage companies. We owe a debt to the people who have mentored us, and we in turn have a responsibility to turn our hard won lessons into a solid foundation for our industry's emerging innovators and leaders.. Previously, Daniel spent time working at ARPA-E and the Center for Climate and Energy Solutions, and has published research examining potential early markets for fusion energy as well as techno-economic synergies between direct air capture and advanced nuclear. I would love to talk to the 1 out of 7 VCs who thinks non-orphan small molecules for older patients are just as investable post His laboratory at the Broad focused on advanced high throughput biotechnology tools including DNA synthesis, single cell analysis, synthetic biology derived biomolecule libraries, and microbiome profiling. He worked previously as the Director of Business Systems at Bain Capital Credit, and as a Senior Systems Analyst at eSecLending, LLC. James McArthur is an Advisor for RA Capital Management. He has served on the Board of Directors of Sojournix, Inc., AltusPharmaceuticals (Nasdaq: ALTU) and the CellScape Corporation. Sophie is a Fellow of the Royal College of Physicians, London, UK. As Director of Global Marketing, she provided global leadership for the launch of Otezla for the treatment of patients with psoriasis and psoriatic arthritis. Neil has spent five years at RA Ventures where he was most recently Vice President, CMC and worked across new company formation and in support of portfolio companies. Vikram studied engineering at the Indian Institute of Technology, Delhi before earning a BS in Operations Research with honors from Columbia University. Matts primary responsibilities at RA Capital are to gather team input to help guide internal software development to support competitive landscapes of drugs and medical devices across a range of disease indications and capabilities, and to provide software training and coordinate with outside technology vendors. Derek holds a BA in Biology from Holy Cross College and a PhD in Pharmacology from the University of Washington. He continues advising both in a consultant capacity. Peter Kolchinsky - Managing Partner - RA Capital Management, LP - LinkedIn Previously, Rebecca worked as a Senior Associate within RAs TechAtlas division. Ben previously worked as a Research Assistant in a Neuroinflammation lab at Brigham and Womens Hospital/Harvard Medical School, and was an Internet Application Developer at the Gallup Organization. Peter Kolchinsky Number of IPOs: 18. Prior to joining RA, Brigid was the Head of Venture Investments for BHP Ventures, the internal venture capital unit within the worlds largest mining company, where her investment mandate was to help the decarbonization of BHPs operations and to improve the sustainability of resource extraction. Prior to his career at the Broad Institute, Robert was an MIT Leaders for Manufacturing Fellow, and a project manager for Fluor Corporation, where he managed large-scale petrochemical design and construction projects. Prior to IGEN Cony worked for Corning in the US and in Europe. While at Acceleron he successfully launched the company's first blockbuster asset - REBLOZYL - and brought in the company's lead drug - Sotatercept - prior to Acceleron's eventual sale to Merck in 2021. Michael is chair of the Board of Managers of the Harvard Pilgrim Health Care Institute. Within the last 20 years alone, PJ Hogan had a go with 2003's Peter Pan (a major, almost $100m-losing flop), Joe Wright tried again in 2015 with the more radical Pan (another massive failure . From 1997-2000, Scott served as General Manager of Biopharmaceuticals, Corporate Vice President of Business Development, and a member of the Board ofDirectors of Altus Pharmaceuticals, Inc (Nasdaq: ALTU). Peter Kolchinsky on Twitter